Regeneron Pharmaceuticals Inc (REGN) reported third-quarter earnings for fiscal 2025 that exceeded analyst expectations. The company posted earnings per share (EPS) of $11.83, significantly above the consensus estimate of $9.78, reflecting a $2.05 positive variance. Revenue reached $3.8 billion, surpassing the anticipated $3.7 billion.
The earnings results highlight Regeneron's robust operational performance in the biotechnology sector. The company specializes in the discovery, development, and commercialization of medicines, employing over 15,000 personnel in Tarrytown, New York. Regeneron's product portfolio includes treatments for serious conditions such as eye diseases, cancer, and rare diseases, utilizing proprietary technologies like VelociSuite for drug development.
Regeneron will host an earnings conference call to discuss these results and provide further insights into its business performance. Upcoming earnings are projected for July 29, 2026, with an estimated EPS of $11.203 and revenue of $3.7 billion, followed by a report on April 26, 2026, estimating an EPS of $10.4652 and revenue of $3.5 billion.
This update provides insight into Regeneron Pharmaceuticals Inc's financial health and operational strength, underscoring its position in the biotechnology industry.